Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UDIZ-002
- Development stage
- Preclinical
- Lead developer
- UDIBI
01
Overview
UDIZ-002 is a preclinical-stage immunomodulator being developed by the Unidad de Desarrollo e Investigación en Bioprocesos (UDIBI) at the Instituto Politécnico Nacional (IPN) in Mexico. As an immunomodulatory agent, it is designed to regulate or modify the immune response, although its specific molecular targets and primary therapeutic indications have not been publicly disclosed. The drug is currently part of UDIBI's internal development pipeline, which focuses on the research and production of biopharmaceuticals.
- Other names
- Immunomodulator UDIZ-002Inmunomodulador UDIZ-002
Beyond the preview
Go deeper on UDIZ-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UDIZ-002.